DIRS.INFO The most relevant business & tech news

The survey also showed that 36% of the nurses plan to continue working in the sector but may change workplaces. "This really underscores the continued mental health and well-being challenges the nursing workforce experiences post pandemic," AMN Healthcare CEO Cary Grace told Reuters in an interview. The survey showed there are various changes needed, with 69% of nurses seeking increased salaries and 63% of them seeking a safer working environment to reduce their stress. This comes at a time hospital operator and sector bellwether HCA Healthcare Inc (HCA.N) indicated a recovery in staffing situation. The staffing crisis drove up costs at hospital operators, while boosted profits at medical staffing providers such as AMN Healthcare.

April 26 (Reuters) - Humana Inc (HUM.N) raised its annual adjusted profit forecast on Wednesday after lower medical costs in the firm's government-backed health insurance business helped it beat profit estimates for the first quarter. Some analysts stressed on increased investor scrutiny into whether certain one-time items were helping lower medical costs artificially. Humana CFO Susan Diamond said the insurer saw favorable cost trends in the quarter even as hospitals reported a recovery in procedures. On an adjusted basis, Humana expects annual profit per share of at least $28.25, compared with its previous forecast of at least $28. For the first quarter, it reported adjusted profit of $9.38 per share, beating estimates of $9.27.

March 28 (Reuters) - Walgreens Boots Alliance Inc (WBA.O) said on Tuesday it does not plan to increase wages further, as a shortage of pharmacists eases after the company doubled down on hiring and pay raises last year. A labor shortage during the pandemic prompted Walgreens and other U.S. drugstore operators, including CVS Health Corp (CVS.N) and Walmart Inc (WMT.N), to raise minimum wages to $15 per hour to attract pharmacists. Shares of the company rose 4.3% to $34.37 in midday trading. The health segment saw a sharp increase in revenue to $1.6 billion, driven by the deals. Reporting by Leroy Leo and Khushi Mandowara in Bengaluru; Editing by Maju Samuel and Rashmi AichOur Standards: The Thomson Reuters Trust Principles.

The Food and Drug Administration made its assessment in briefing documents ahead of a meeting of the agency's external advisers on Thursday to discuss full approval to use Pfizer's oral pill for high-risk COVID-19 patients exhibiting mild to moderate symptoms. Paxlovid has been authorized for emergency use since late 2021, and a full approval is likely to allow Pfizer to expand its advertising campaign for the drug. Over 12 million courses have been delivered to pharmacies, and patients have used over 8 million courses of the treatment, according to Federal data. Paxlovid has shown reduction in risk of hospitalization or death by 86% in non-hospitalized, high-risk adult patients in Pfizer' study, which did not include vaccinated participants. Reporting by Leroy Leo and Khushi Mandowara in Bengaluru; Editing by Shailesh Kuber and Shinjini GanguliOur Standards: The Thomson Reuters Trust Principles.

Companies Humana Inc FollowFeb 1 (Reuters) - Humana Inc (HUM.N) on Wednesday beat Wall Street estimates for quarterly profit as the health insurer's investment income jumped, even as the company reported higher-than-expected medical costs. Health insurers' costs were expected to decline on lower COVID-19-related hospitalizations, though there were concerns around a surge in flu and respiratory syncytial virus cases in the last quarter of 2022. The health insurer said it expects to add at least 625,000 members to its Medicare Advantage plan this year. Excluding one-off items, the health insurer reported a profit of $1.62 per share, higher than analysts' average estimate of $1.46 per share, according to Refinitiv data. The company's $160 million investment income was higher than Wall Street estimates of $136.7 million, Oppenheimer analyst Michael Wiederhorn said.

Dec 8 (Reuters) - General Electric Co's (GE.N) healthcare division is aiming to have a medium-term organic revenue growth in the mid-single-digits, the unit's Chief Executive Officer Peter Arduini said at an investor day conference on Thursday. China, which accounts for about 15% of total GE Healthcare sales, would also help drive growth as there is a pent-up demand in the market, Arduini said. GE Healthcare also expects medium-term adjusted core earnings margin to be close to 20%. Zodl highlighted challenges such as macroeconomic factors, supply chain challenges, restructuring action undertaken in 2022 along with planned investment in research and development which may weigh on its core earnings margin. The healthcare company had revenue of around $18 billion last year, with about half of it from recurring sources, GE Healthcare said in a presentation.

Search resuls for: "Khushi Mandowara Leroy Leo"

6 mentions found